WEZLANA
Wezlana is a human interleukin-12 and -23 antagonist indicated for the treatment of several chronic inflammatory conditions in both adult and pediatric populations. In adults, it is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease or ulcerative colitis. Pediatric patients aged 6 years and older may receive the treatment for moderate to severe plaque psoriasis and active psoriatic arthritis. It is specifically indicated for psoriasis patients who are candidates for phototherapy or systemic therapy.
How WEZLANA Works
Wezlana is a monoclonal antibody that binds to the p40 protein subunit shared by the IL-12 and IL-23 cytokines. By targeting this subunit, the drug prevents these cytokines from interacting with the IL-12Rβ1 receptor on the surface of cells. This disruption inhibits signaling cascades that lead to natural killer cell activation and T-cell differentiation. This mechanism addresses the chronic inflammation that characterizes immune-mediated diseases like Crohn's disease and ulcerative colitis.
Details
- Status
- Prescription
- First Approved
- 2023-10-31
- Routes
- INTRAVENOUS, SUBCUTANEOUS
- Dosage Forms
- INJECTABLE
WEZLANA Approval History
What WEZLANA Treats
4 indicationsWEZLANA is approved for 4 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Plaque Psoriasis
- Psoriatic Arthritis
- Crohn's Disease
- Ulcerative Colitis
WEZLANA Target & Pathway
ProTarget
A cytokine that promotes Th17 cell development and maintenance. IL-23 is upstream of IL-17 in the inflammatory cascade driving psoriasis and inflammatory bowel disease. Blocking IL-23 provides sustained control of these conditions.
Pharmacists can substitute WEZLANA for Stelara without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
WEZLANA Competitors
Pro6 other drugs also target IL-12. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (IL-12). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to WEZLANA
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
WEZLANA FDA Label Details
ProIndications & Usage
FDA Label (PDF)WEZLANA is a human interleukin -12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. active psoriatic arthritis (PsA) . moderately to severely active Crohn's disease (CD) . moderately to severely active ulcerative colitis. Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO) , who are candidates for phototherapy or systemic therapy. active psoriatic arthritis (PsA) . 1.1 Plaque Psoriasis (PsO) WEZLANA is indicated for the treatment of adults a...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.